medigraphic.com
ISSN 2992-779X (Electronic)
ISSN 2007-6452 (Print)

2015, Number 2

<< Back Next >>

Investigación en Discapacidad 2015; 4 (2)

Pharmaco-toxicity of vehicles in drug therapy for Parkinson disease

Krötzsch E

Language: Spanish
References: 21
Page: 86-90
PDF size: 154.50 Kb.


ABSTRACT

Drug treatment for neurodegenerative disorders such as Parkinsonism, are intended to improve or moderate symptoms in spite of their potential systemic toxic effects. Pharmaceutical nanotechnology focusing on vehiculization of drugs was expected to improve effectiveness on drug administration. However body responses have not always resulted as expected, since the hemato-encephalic barrier still plays her roll on drug transportation. Detoxification process of drugs and their vehicles can modify the expected clinical response to treatment. A hope arises to drug transportation, either by vehicles or by loaded cells with nanoparticles into specific targets through the central nervous system with no significant loss of power or systemic toxicity. Mechanisms of cell-drug transportation are still unsolved, even more to focus on cell tropism into specific targets since cells are exposed to a variety of stimuli capable to modify their direction, metabolism or even death by apoptosis.


REFERENCES

  1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311 (16): 1670-1683.

  2. Kim SN, Doo AR, Park JY, Choo HJ, Shim I, Park JJ et al. Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson’s disease-induced neurochemica limbalance. Brain Res. 2014; 1544: 33-44.

  3. Fernández M, Barcia E, Fernández-Carballido A, Garcia L, Slowing K, Negro S. Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson’s disease. Int J Pharm. 2012; 438 (1-2): 266-278.

  4. Fernández M, Negro S, Slowing K, Fernández-Carballido A, Barcia E. An effective novel delivery strategy of rasagiline for Parkinson’s disease. Int J Pharm. 2011; 419 (1-2): 271-280.

  5. Giordano C, Albani D, Gloria A, Tunesi M, Rodilossi S, Russo T et al. Nanocomposites for neurodegenerative diseases: hydrogel-nanoparticle combinations for a challenging drug delivery. Int J Artif Organs. 2011; 34 (12): 1115-1127.

  6. Li T, Shi T, Li X, Zeng S, Yin L, Pu Y. Effects of nano-MnO2 on dopaminergic neurons and the spatial learning capability of rats. Int J Environ Res Public Health. 2014; 11 (8): 7918-7930.

  7. Fernandes C, Soni U, Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol Res. 2010; 62 (2): 166-178.

  8. Jain V, Jain S, Mahajan SC. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv. 2014; Aug 22. En prensa.

  9. Elsaesser A, Howard CV. Toxicology of nanoparticles. Adv Drug Deliv Rev. 2012; 64 (2): 129-137.

  10. Hwang SR, Kim K. Nano-enabled delivery systems across the blood-brain barrier. Arch Pharm Res. 2014; 37 (1): 24-30.

  11. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J et al. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010; 40 (5): 385-403.

  12. Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol. 2009; 88 (4): 272-285.

  13. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2012; 41 (7): 2780-2799.

  14. Nowacek A, Kosloski LM, Gendelman HE. Neurodegenerative disorders and nano formulated drug development. Nanomedicine (Lond). 2009; 4 (5): 541-555.

  15. Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGyla ted therapeutics. Drug Discov Today. 2014. pii: S1359-6446(14)00342-0. En prensa.

  16. O’Loughlin AJ, Woffindale CA, Wood MJ. Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Ther. 2012; 12 (4): 262-274.

  17. Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, Klyachko NL et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson’s disease. Nanomedicine (Lond). 2010; 5 (3): 379-396.

  18. Arora P, Sindhu A, Dilbaghi N, Chaudhury A, Rajakumar G, Rahuman AA. Nano-regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans. J Cell Mol Med. 2012; 16 (9): 1991-2000.

  19. Bose T, Latawiec D, Pratim MP, Mandal S. Overview of nano-drugs characteristics for clinical application: the journey from the entry to the exit point. J Nanopart Res. 2014; 16: 2527.

  20. Pehlivan SB. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res. 2013; 30 (10): 2499-2511.

  21. Li Y, Zhang Y, Yan B. Nanotoxicity overview: nano-threat to susceptible populations. Int J Mol Sci. 2014; 15 (3): 3671-3697.




2020     |     www.medigraphic.com